Association of anti-citrullinated protein antibodies with changes in bone density in patients with rheumatoid arthritis treated with romosozumab for one year: A cohort study
- 3 June 2025
- journal article
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 35 (6) , 1079-1081
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case–control studyOsteoporosis International, 2024
- Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot studyModern Rheumatology, 2022
- Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administrationModern Rheumatology, 2022
- Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid ArthritisArthritis & Rheumatology, 2020
- Cubic splines to model relationships between continuous variables and outcomes: a guide for cliniciansBone Marrow Transplantation, 2019
- Titer-Dependent Effect of Anti-Citrullinated Protein Antibodies On Systemic Bone Mass in Rheumatoid Arthritis PatientsCalcified Tissue International, 2017
- Romosozumab Treatment in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2016
- The number of subjects per variable required in linear regression analysesJournal of Clinical Epidemiology, 2015
- Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodiesAnnals of the Rheumatic Diseases, 2014
- 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiativeAnnals of the Rheumatic Diseases, 2010